Mangoceuticals Inc (MGRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-05
$0.19-7.39%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-05
QuarterlyIQ Insights · MGRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The proceeds are intended to advance the commercialization of MangoRx IP’s intellectual property portfolio.
Stated in a supplied disclosure. Management reported: “The proceeds are intended to advance the commercialization of MangoRx IP’s intellectual property portfolio.” ““We believe that this investment represents an important validation of the value we have built within MangoRx IP Holdings and provides us with additional capital to advance the next phase of commercialization, without issuing a single share of MGRX common stock,” said Jacob Cohen, Founder and Chief Executive Officer of Mangoceuticals.” Revenue was $0.069 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Transaction Details The approximately $500,000 registered direct offering closed on October 9, 2026.
Stated in a supplied disclosure. Management reported: “Transaction Details The approximately $500,000 registered direct offering closed on October 9, 2026.” “The unit purchase price represents an approximately 74% premium to the Company’s referenced recent closing share price of $0.43.”
We intend to build on this momentum as we advance commercialization initiatives and evaluate opportunities to create long-term shareholder value.”
Stated in a supplied disclosure. Management reported: “We intend to build on this momentum as we advance commercialization initiatives and evaluate opportunities to create long-term shareholder value.””
Address Nasdaq Listing Rule 5550(a)(2) non-compliance due to low stock price to regain compliance.
Pursue the business combination with Nuclea Energy Inc. to expand operations.
Over the trailing year it converted 0.49x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
58 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.